BIO Stock Price, Bio-Rad Laboratories Inc Quote, Chart

Market Summary

USD281.54+1.81

Delayedas of 22 Apr 2024, 03:32 pm

0.65%

BIO Stock Price

View Fullscreen

BIO RSI Chart

BIO Valuation

Market Cap

8.2B

Price/Earnings (Trailing)

-12.81

Price/Sales (Trailing)

3.06

EV/EBITDA

-11.19

Price/Free Cashflow

37.4

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-31.82%

Return on Equity

-7.29%

Return on Assets

-5.18%

Free Cashflow Yield

2.67%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.7B

Rev. Growth (Yr)

-6.72%

Rev. Growth (Qtr)

7.77%

BIO Earnings

Earnings (TTM)

-637.3M

Earnings Growth (Yr)

-57.75%

Earnings Growth (Qtr)

228.97%

Breaking Down BIO Revenue

52 Week Range

277.71473.50

(Low)(High)

Last 7 days

-7.0%

Last 30 days

-16.9%

Last 90 days

-8.9%

Trailing 12 Months

-39.1%

How does BIO drawdown profile look like?

BIO Financial Health

Current Ratio

5.83

Debt/Equity

0.14

Debt/Cashflow

0.31

BIO Investor Care

Buy Backs (1Y)

1.93%

Diluted EPS (TTM)

-21.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.8B	2.8B	2.7B	2.7B
2022	2.9B	2.9B	2.8B	2.8B
2021	2.7B	2.9B	3.0B	2.9B
2020	2.3B	2.3B	2.4B	2.5B
2019	2.3B	2.3B	2.3B	2.3B
2018	2.2B	2.3B	2.3B	2.3B
2017	2.1B	2.1B	2.1B	2.2B
2016	2.0B	2.0B	2.1B	2.1B
2015	2.1B	2.1B	2.0B	2.0B
2014	2.1B	2.2B	2.2B	2.2B
2013	2.1B	2.1B	2.1B	2.1B
2012	2.1B	2.1B	2.0B	2.1B
2011	2.0B	2.0B	2.1B	2.1B
2010	1.8B	1.9B	1.9B	1.9B
2009	0	1.8B	1.8B	1.8B
2008	0	0	0	1.8B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Which funds bought or sold BIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Diversified Trust Co	added	259	1,525,000	2,060,350	0.06%
Apr 18, 2024	Oak Thistle LLC	sold off	-100	-617,689	-	-%
Apr 18, 2024	VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.	added	32.38	613,000	2,079,000	0.02%
Apr 18, 2024	SJS Investment Consulting Inc.	unchanged	-	69.00	1,038	-%
Apr 18, 2024	Aspire Private Capital, LLC	unchanged	-	184	2,767	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	added	3.23	1,000	11,000	-%
Apr 18, 2024	Hexagon Capital Partners LLC	unchanged	-	1,654	24,903	0.01%
Apr 18, 2024	BKM Wealth Management, LLC	sold off	-100	-18,081	-	-%
Apr 18, 2024	STATE OF MICHIGAN RETIREMENT SYSTEM	unchanged	-	132,135	1,988,750	0.01%
Apr 18, 2024	MV CAPITAL MANAGEMENT, INC.	reduced	-6.67	-2.00	9,685	-%

Are Funds Buying or Selling BIO?

Are funds buying BIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIO

No. of Funds

Unveiling Bio-Rad Laboratories Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	vanguard group inc	10.36%	2,427,137	SC 13G/A
Feb 13, 2024	vanguard group inc	9.93%	2,389,889	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	1,466,226	SC 13G/A
Feb 09, 2023	vanguard group inc	9.66%	2,391,436	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	1,582,313	SC 13G/A
Apr 11, 2022	schwartz alice n	89.7%	4,555,452	SC 13D/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Feb 09, 2022	vanguard group inc	9.21%	2,287,465	SC 13G/A
Feb 01, 2022	blackrock inc.	7.1%	1,768,081	SC 13G/A

Recent SEC filings of Bio-Rad Laboratories Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	3	Insider Trading
Apr 10, 2024	8-K	Current Report
Mar 27, 2024	ARS	ARS
Mar 27, 2024	DEF 14A	DEF 14A
Mar 20, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Bio-Rad Laboratories Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.2B	40.1B	-3.77%	-2.76%	32.53	4.64	-8.12%	-17.45%
BDX	67.7B	19.5B	-1.53%	-10.57%	53.87	3.47	4.02%	-22.04%
ALGN	22.5B	3.9B	-9.16%	-15.16%	50.45	5.81	3.42%	23.09%
BAX	20.0B	14.8B	-5.62%	-8.72%	7.55	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-0.49%	17.01%	32.33	2.64	4.97%	18.89%
HSIC	9.1B	12.3B	-5.22%	-14.61%	21.9	0.74	-2.44%	-22.68%
BIO	8.2B	2.7B	-16.90%	-39.13%	-12.81	3.06	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.41%	-25.34%	-47.02	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-2.66%	12.41%	-562.64	9.32	33.86%	89.83%
PDCO	2.3B	6.6B	-4.93%	-3.92%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.2B	3.2B	-14.38%	-20.49%	-1.83	0.39	7.73%	-1066.14%
ANIK	383.7M	166.7M	0.86%	-5.21%	-4.64	2.3	6.67%	-456.34%
ANGO	250.7M	324.0M	11.81%	-29.38%	-1.3	0.77	-3.19%	-337.41%
APYX	45.7M	52.3M	-28.65%	-55.25%	-2.44	0.87	17.61%	19.28%
AEMD	3.8M	3.7M	-10.98%	147.46%	-0.31	1.02	5.77%	8.23%

Bio-Rad Laboratories Inc News

Latest updates

Bio-Rad Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	7.8%	681	632	681	677	730	681	691	700	733	747	716	727	790	647	537	572	625	561	573	554	617
Gross Profit	9.1%	366	336	363	362	397	373	395	403	400	437	401	401	460	367	293	317	330	307	308	312	333
S&GA Expenses	3.0%	207	201	208	226	212	211	208	197	222	216	213	226	218	198	189	194	214	202	201	208	214
R&D Expenses	46.8%	64.00	44.00	65.00	75.00	66.00	67.00	64.00	60.00	59.00	64.00	63.00	74.00	57.00	60.00	52.00	49.00	57.00	48.00	50.00	48.00	53.00
EBITDA Margin	-488.9%	-0.30*	-0.05*	-0.17*	-0.07*	-1.67*	-2.78*	-	-0.08*	1.86*	2.87*	1.82*	2.02*	1.99*	1.97*	1.17*	0.94*	1.05*	0.30*	0.60*	0.41*	0.30*
Interest Expenses	-0.3%	12.00	12.00	12.00	12.00	12.00	12.00	11.00	4.00	0.00	0.00	0.00	0.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Income Taxes	155.0%	79.00	31.00	-338	16.00	264	-44.51	-295	-1,000	-461	1,094	243	320	242	370	280	213	146	-76.40	171	262	-212
Earnings Before Taxes	212.5%	428	137	-1,500	85.00	1,091	-207	-1,220	-4,368	-2,027	5,022	1,157	1,297	1,089	1,685	1,246	899	699	-335	770	1,127	-1,041
EBT Margin	-362.4%	-0.32*	-0.07*	-0.19*	-0.09*	-1.68*	-2.79*	-0.90*	-0.07*	1.86*	2.87*	1.82*	1.97*	1.93*	1.90*	1.09*	0.87*	0.98*	0.23*	0.53*	0.34*	0.22*
Net Income	229.0%	350	106	-1,162	69.00	828	-162	-925	-3,367	-1,572	3,930	917	980	839	1,315	966	686	554	-258	599	865	-828
Net Income Margin	-307.4%	-0.24*	-0.06*	-0.15*	-0.07*	-1.29*	-2.15*	-0.67*	-0.03*	1.46*	2.24*	1.41*	1.52*	1.50*	1.48*	0.85*	0.68*	0.76*	0.16*	0.40*	0.25*	0.16*
Free Cashflow	-27.8%	39.00	54.00	63.00	62.00	45.00	-16.54	36.00	17.00	115	196	131	94.00	245	116	74.00	41.00	138	69.00	133	19.00	51.00

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	3.4%	12,299	11,896	11,978	13,667	13,502	12,058	12,682	14,374	17,799	19,953	15,118	13,933	12,973	12,021	10,097	8,684	8,009	7,177	7,647	6,863	5,611
Current Assets	-3.1%	3,048	3,147	3,139	3,277	3,158	3,140	3,250	3,303	1,990	2,466	2,289	2,175	2,140	2,324	2,133	2,083	2,180	2,048	2,088	2,032	2,023
Cash Equivalents	-11.8%	404	458	390	464	434	518	597	802	471	860	733	673	667	840	608	604	663	561	581	456	434
Inventory	0.6%	781	776	777	753	719	686	657	605	572	589	599	605	622	640	628	557	554	588	590	590	584
Net PPE	-	529	-	-	-	499	-	-	-	512	-	-	-	491	-	-	486	499	496	499	503	509
Goodwill	1.6%	414	407	412	408	406	400	347	346	347	292	292	292	292	292	292	264	264	264	235	231	220
Liabilities	2.2%	3,558	3,480	3,531	3,904	3,886	3,605	3,760	4,191	4,114	4,621	3,523	3,324	3,093	3,196	2,744	2,391	2,254	2,046	2,160	1,999	1,591
Current Liabilities	-6.3%	523	558	582	590	569	571	614	648	681	650	587	610	632	987	927	869	905	434	446	444	451
Long Term Debt	0.0%	1,199	1,199	1,198	1,198	1,198	1,197	1,197	1,197	11.00	11.00	11.00	11.00	12.00	12.00	12.00	12.00	14.00	438	438	438	439
LT Debt, Non Current	-100.0%	-	1,199	1,198	1,198	1,198	1,197	1,197	1,197	11.00	11.00	11.00	11.00	12.00	12.00	12.00	12.00	14.00	438	438	438	439
Shareholder's Equity	3.9%	8,741	8,416	8,447	9,764	9,615	8,477	8,945	10,203	13,685	15,332	11,595	10,609	9,890	8,825	7,353	6,293	5,757	5,131	5,487	4,864	4,020
Retained Earnings	3.9%	9,261	8,911	8,805	9,967	9,898	9,047	9,210	10,138	13,525	15,081	11,159	10,245	9,268	8,429	7,123	6,157	5,471	4,917	5,185	4,586	3,722
Additional Paid-In Capital	2.2%	449	439	474	463	447	431	472	459	442	421	460	445	429	412	429	424	410	396	411	403	394
Accumulated Depreciation	-	-	-	-	-	1,009	-	-	-	1,002	-	-	-	961	-	-	876	883	851	850	828	818
Shares Outstanding	0.4%	29.00	29.00	29.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00
Float	-	-	-	7,746	-	-	-	68.00	-	-	-	13,641	-	-	-	9,502	-	-	-	6,613	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-17.1%	81,000	97,715	98,066	98,119	79,610	10,990	53,306	50,494	170,900	230,366	154,624	113,610	294,400	135,700	92,092	62,808	159,802	99,750	155,445	42,900	104,994
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,800	-	-	-	9,100	-	-	-
Cashflow From Investing	860.0%	72,197	-9,500	27,984	-70,473	-58,552	-88,419	-144,481	-916,141	-567,427	-81,350	-100,277	-48,327	-59,753	90,854	-88,573	-12,422	-61,196	-109,909	-15,071	-22,713	-54,811
Cashflow From Financing	-654.3%	-200,620	-26,598	-202,738	4,309	-86,619	-8,772	-121,326	1,190,293	4,635	-15,582	2,865	-47,347	-421,884	439	-2,979	-98,617	-4,783	-4,491	-15,645	2,161	-47,003
Buy Backs	838.0%	200,000	21,321	-	-	90,679	-	125,000	-	-	-	-	49,998	-	-1.00	-	100,005	8,000	4,999	15,001	-	48,912

BIO Income Statement

2023-12-31

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net sales	$ 681,200	$ 632,100	$ 681,100	$ 676,800	$ 730,300	$ 680,800	$ 691,100	$ 700,100	$ 2,671,262	$ 2,802,249	$ 2,922,545
Cost of goods sold									1,244,316	1,234,919	1,284,449
Gross profit	366,300	335,700	362,500	362,400	397,100	372,600	395,000	402,600	1,426,946	1,567,330	1,638,096
Selling, general and administrative expense									841,723	827,825	877,122
Research and development expense									247,427	256,889	260,638
Income from operations									337,796	482,616	500,336
Interest expense									49,439	38,114	1,551
Foreign currency exchange (gains) losses, net									(7,347)	(205)	2,753
(Gains) losses from change in fair market value of equity securities and loan receivable									1,252,251	5,193,554	(4,926,248)
Other income, net									(106,443)	(44,574)	(26,775)
Net income (loss) before income taxes									(850,104)	(4,704,273)	5,449,055
Benefit from (Provision for) income taxes									212,780	1,076,738	(1,194,798)
Net income (loss)	$ 349,700	$ 106,300	$ (1,162,300)	$ 69,000	$ 827,700	$ (162,800)	$ (925,100)	$ (3,367,300)	$ (637,324)	$ (3,627,535)	$ 4,254,257
Basic earnings (loss) per share:
Net income (loss) per basic share (in dollars per share)	$ 12.15	$ 3.65	$ (39.59)	$ 2.33	$ 27.89	$ (5.48)	$ (31.05)	$ (112.50)	$ (21.82)	$ (121.79)	$ 142.61
Weighted average common shares - basic (in shares)									29,209	29,785	29,831
Diluted earnings (loss) per share:
Net income (loss) per diluted share (in dollars per share)	$ 12.14	$ 3.64	$ (39.59)	$ 2.32	$ 27.78	$ (5.48)	$ (31.05)	$ (112.50)	$ (21.82)	$ (121.79)	$ 140.83
Weighted average common shares - diluted (in shares)									29,209	29,785	30,208

BIO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 403,815	$ 434,215
Short-term investments	1,203,327	1,356,457
Restricted investments	5,560	5,560
Restricted investments	489,017	494,645
Inventory	780,517	719,316
Prepaid expenses	140,040	124,179
Other current assets	26,054	23,604
Total current assets	3,048,330	3,157,976
Property, plant and equipment, net	529,007	498,612
Operating lease right-of-use assets	194,730	180,952
Goodwill, net	413,569	406,488
Purchased intangibles, net	320,514	332,147
Other investments	7,698,070	8,830,892
Other assets	94,850	94,599
Total assets	12,299,070	13,501,666
Current liabilities:
Accounts payable	144,625	135,041
Accrued payroll and employee benefits	139,929	194,790
Current maturities of long-term debt and notes payable	486	465
Income and other taxes payable	35,759	32,428
Current operating lease liabilities	40,379	36,336
Other current liabilities	161,621	169,648
Total current liabilities	522,799	568,708
Long-term debt, net of current maturities	1,199,052	1,197,716
Deferred income taxes	1,475,495	1,770,481
Operating lease liabilities	165,478	153,597
Other long-term liabilities	195,113	195,912
Total liabilities	3,557,937	3,886,414
Commitments and contingent liabilities
Stockholders’ equity:
Additional paid-in capital	449,075	447,454
Class A treasury stock at cost, 1,747,438 shares at 2023 and 640,492 shares at 2022	(632,536)	(263,586)
Retained earnings	9,260,629	9,898,203
Accumulated other comprehensive loss	(336,038)	(466,822)
Total stockholders’ equity	8,741,133	9,615,252
Total liabilities and stockholders’ equity	12,299,070	13,501,666
Common Class A
Stockholders’ equity:
Common stock	2	2
Common Class B
Stockholders’ equity:
Common stock	$ 1	$ 1

About Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

CEO	Mr. Norman D. Schwartz
WEBSITE	bio-rad.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	8200

Bio-Rad Laboratories Inc Frequently Asked Questions

What is the ticker symbol for Bio-Rad Laboratories Inc? What does BIO stand for in stocks?

BIO is the stock ticker symbol of Bio-Rad Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Rad Laboratories Inc (BIO)?

As of Fri Apr 19 2024, market cap of Bio-Rad Laboratories Inc is 8.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers. The fair value of Bio-Rad Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Rad Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Rad Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether BIO is over valued or under valued. Whether Bio-Rad Laboratories Inc is cheap or expensive depends on the assumptions which impact Bio-Rad Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIO.

What is Bio-Rad Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, BIO's PE ratio (Price to Earnings) is -12.81 and Price to Sales (PS) ratio is 3.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Rad Laboratories Inc's stock?

In the past 10 years, Bio-Rad Laboratories Inc has provided 0.085 (multiply by 100 for percentage) rate of return.